In this edition of #StaffSpotlight, we present Jaume Vidal, a Policy Advisor on Health Action International’s (HAI) European Projects team. When you see Jaume in the office, he’s often teasing Alex, our Communications Advisor, eating a kiwi, or showing someone a picture of his new baby son. But on top of his charismatic social presence,
by MAARTEN VAN DER HEIJDEN, Policy Associate, ReAct – Action on Antibiotic Resistance
Last week, the Second Consultation of Member States and Partners on the Global Development and Stewardship Framework to Combat Antimicrobial Resistance (AMR) took place. Like the last meeting in November 2017, non-state actors were invited to participate in the first of the meeting,
Guest blog by FEMKE HEDDEMA, former HAI intern
Last week, we held a successful event in The Hague on public health and innovation in the Netherlands. The success of the event owed a lot to the hard work and dedication of our summer intern, Femke, who writes here on her experiences and what she learned working with us at HAI.
by DR ASHTON BARNETT-VANES
It’s been a busy week at HAI, in which we’ve hosted events in the Netherlands (on alternative models of innovation) and the United States (on non-communicable diseases and access to insulin) , and seen the launch of an exciting new paper on the cost of production of insulin.
By GABY OOMS, Research Officer
Afgelopen week mocht ik na 1,5 jaar weer voor een week achter de schoolbanken schuiven voor het vak ‘pharmaceutical policy analysis’ die werd georganiseerd door de Utrecht Summer School.
by ALEX LAWRENCE, Communications Advisor
At the 71st World Health Assembly, the great and the good (and sometimes, not so good) of global health came together on some of the most pressing health challenges we face.
On the agenda, and of particular interest to Health Action International (HAI), were the World Health Organization’s (WHO) General Programme of Work (GPW13),
by ANCEL.LA SANTOS, Senior Policy Advisor
The formal engagement of patients and consumers in the pharmaceutical regulatory process helps ensure that important decisions about medicines take into account the thoughts and views of the people they most affect. The European Medicines Agency (EMA) has a long tradition of this kind of stakeholder involvement.
The old saying that “money makes the world go round” is especially true for non-governmental organisations, like ours. Without it, HAI wouldn’t be able to realise our access to medicines goals all over the world. But with every funding success of the project and funding teams, we owe it to our donors, the public and,